Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ziff Capital Partners
Deal Size : $54.0 million
Deal Type : Series A Financing
Corner Therapeutics Raises $54M in Series A for Lifelong Immunity Vaccines
Details : The net proceeds will be used to create vaccines against cancer and infectious disease, using Corner's antigen agnostic technology, which is focused on natural intelligence of body’s dendritic cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ziff Capital Partners
Deal Size : $54.0 million
Deal Type : Series A Financing